A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 795 participants.

Also called NCT05662332

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 795 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05662332
Other papers using this trial's data
  • Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy The New England journal of medicine, 2025-07-24 DOI, PubMed 40548694

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Mexico, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05662332. Randomized; no masking; primary purpose treatment. Start 2023-01-14 (actual); primary completion 2024-07-19 (actual). Results posted on 2025-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
Acronym
QWINT-1
Condition
T2D
Intervention (Drug)
Insulin Efsitora Alfa
Intervention (Drug)
Insulin Glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05662332
Content hash
065ad84fb1cf66eef420842b6c2c0a20514351181d1744d90b4b94fa46e28948